|
Feb 22
|
Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease
|
|
Feb 22
|
Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease
|
|
Feb 19
|
Press Release: Sanofi and CD&R sign Opella share purchase agreement
|
|
Feb 18
|
Press Release: Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid
|
|
Feb 7
|
Press Release: Execution of a share buyback agreement for up to €2 billion
|
|
Feb 4
|
Regeneron Pharmaceuticals Beats On Libtayo's Back, Unveils Dividend
|
|
Feb 3
|
Press Release: Sanofi announces buy back of shares from L’Oréal
|